Gritstone bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Gritstone bio, a clinical-stage biotechnology firm (Nasdaq: GRTS), announced participation in key investor conferences set for January and February 2023. Andrew Allen, Co-founder and CEO, will lead discussions at the B. Riley Oncology Conference on January 19 and the SVB Securities Global Biopharma Conference on February 16. Celia Economides, CFO, will join a panel at the BIO CEO & Investor Conference on February 6. The events aim to address industry challenges, including CRO spending in a high-inflation environment. Archived replays will be available post-events to provide insights into Gritstone's innovative vaccine development.

EMERYVILLE, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will participate in the following investor conferences.

B. Riley Securities' 3^rd Annual Oncology Conference (Fireside Chat)
Date and Time: Thursday, January 19, 2023 at 12:30pm ET
Presenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer

2023 BIO CEO & Investor Conference (Panel)
Panel Title: Prioritizing CRO Spending Through a High-Inflation, Sparse-Funding Period
Date and Time: Monday, February 6, 2023 at 2:00pm ET
Presenter: Celia Economides, Chief Financial Officer

SVB Securities Global Biopharma Conference (Fireside Chat)
Date and Time: Thursday, February 16, 2023 at 1:40pm ET
Presenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer

Live webcast and/or archived replays will be available via https://ir.gritstonebio.com/investors/events. Archived replays will be accessible for at least 30 days following the corresponding event.

About Gritstone bio
Gritstone is working to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets and have programs in viral diseases and solid tumors. Independently and with our partners, we are advancing a portfolio of product candidates with the aim of improving patient outcomes and eliminating disease. www.gritstonebio.com

Gritstone Contacts
Investors:
George E. MacDougall
Director, Investor Relations & Corporate Communications
Gritstone bio, Inc.
ir@gritstone.com

Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com

FAQ

What investor conferences is Gritstone bio participating in January 2023?

Gritstone bio is participating in B. Riley Securities' Oncology Conference on January 19 and the BIO CEO & Investor Conference on February 6.

Who will present at the B. Riley Securities' Oncology Conference?

Andrew Allen, M.D., Ph.D., Co-founder and CEO of Gritstone bio, will present at the B. Riley Securities' Oncology Conference.

What is the focus of the BIO CEO & Investor Conference panel?

The panel at the BIO CEO & Investor Conference will focus on prioritizing CRO spending during high-inflation and sparse-funding periods.

When is Gritstone bio's SVB Securities Global Biopharma Conference presentation?

Gritstone bio's presentation at the SVB Securities Global Biopharma Conference is scheduled for February 16, 2023.

Where can I find replays of Gritstone bio's conference presentations?

Archived replays of Gritstone bio's conference presentations will be available on their investor events page for at least 30 days after each event.